Joyce O’Shaughnessy, MD - Evidence Informing Practice: Changing Standards of Care for Use of CDK4 and 6 Inhibitors in the Treatment of Breast Cancer

Go online to PeerView.com/GVH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent approval of newer JAK inhibitors and new evidence on emerging JAK-targeting strategies have raised additional questions over optimized treatment selection in myelofibrosis (MF) and awareness of clinical factors that can influence therapeutic selection. Additionally, newer dynamic risk-assessment models have allowed for more precise characterization of this disease at diagnosis and during the treatment course. In the wake of these advances, understanding how to effectively personalize therapeutic management based on the modern diagnostic and risk-assessment tools while ensuring safe usage of JAK inhibitors is crucial to maximizing beneficial patient outcomes in MF. In a recent live webcast, our panel of experts used the latest real-world evidence to confirm the core therapeutic role for JAK inhibitor–based strategies in MF, highlighting modern diagnostic and risk-assessment strategies that have informed an individualized treatment approach. During a unique practicum session, the panel offered practice strategies using real-world case scenarios, walking through selection of JAK inhibitor–based options across the MF disease continuum to improve patient outcomes. Upon completion of this activity, participants should be better able to: Recognize clinical and molecular/mutational features that can be used for diagnosis and risk stratification in myelofibrosis, Review the latest efficacy and safety evidence about approved and emerging JAK inhibitors as well as other targeted therapies in the management of myelofibrosis, Design safe, risk-adapted treatment regimens for patients with symptomatic and asymptomatic myelofibrosis, including those refractory to front-line JAK inhibitor therapy.